Industrial Production

Capacity that lasts

Manufacturing capacity is the backbone of health sovereignty. The Emerging Biopharmaceuticals network brings together producers that already operate GMP facilities for vaccines, biosimilars and biologics, and those that are scaling up.

The lesson of the pandemic is that capacity must be kept active between emergencies. That requires predictable demand, competitive costs and quality systems recognised by regulators and procurers worldwide.

What the hub does

• Industrial production cooperation and scaling: matching members for technology transfer, contract manufacturing and shared capacity.
• Benchmarking of GMP facilities, technology platforms and regional industrial clusters, together with the Data Driver.
• Sessions with technology and service partners on cost-efficient manufacturing, such as the WuXi Vaccines webinar on accessible biologics.
• Experience sharing on regulatory certification, prequalification and quality systems.